Drugging the undruggable RAS: Mission Possible?

被引:0
|
作者
Adrienne D. Cox
Stephen W. Fesik
Alec C. Kimmelman
Ji Luo
Channing J. Der
机构
[1] Lineberger Comprehensive Cancer Center,
[2] University of North Carolina at Chapel Hill,undefined
[3] Vanderbilt University School of Medicine,undefined
[4] Dana-Farber Cancer Institute,undefined
[5] National Cancer Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Attempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.
引用
收藏
页码:828 / 851
页数:23
相关论文
共 50 条
  • [1] Drugging the undruggable RAS: Mission Possible?
    Cox, Adrienne D.
    Fesik, Stephen W.
    Kimmelman, Alec C.
    Luo, Ji
    Der, Channing J.
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (11) : 828 - 851
  • [2] Drugging the Undruggable Ras - Immunotherapy to the Rescue?
    June, Carl H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (23): : 2286 - 2289
  • [3] Drugging the Undruggable: Advances on RAS Targeting in Cancer
    Molina-Arcas, Miriam
    Samani, Amit
    Downward, Julian
    GENES, 2021, 12 (06)
  • [4] DRUGGING THE "UNDRUGGABLE"
    Verdine, Gregory L.
    DRUGS OF THE FUTURE, 2009, 34 : 46 - 47
  • [5] Drugging the undruggable: Small molecule inhibition of the Ras oncoprotein
    Maurer, Till
    Garrenton, Lindsay
    Oh, Angela
    Pitts, Keith
    Skelton, Nicholas
    Fauber, Benjamin
    Pan, Borlan
    Malek, Shiva
    Stokoe, David
    Bowman, Krista
    Wu, Jiansheng
    Giannetti, Anthony
    Starovasnik, Melissa
    Mellman, Ira
    Jackson, Peter
    Rudolph, Joachim
    Wang, Weiru
    Fang, Guowei
    CANCER RESEARCH, 2012, 72
  • [6] Therapeutic targeting of RAS: New hope for drugging the "undruggable"
    Khan, Imran
    Rhett, J. Matthew
    O'Bryan, John P.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2020, 1867 (02):
  • [7] Drugging the undruggable
    Wells, James A.
    Wolan, Dennis
    Zorn, Julie
    Datta, Debajyoti
    Gray, Daniel
    Sadowsky, Jack
    McClendon, Chris
    Arkin, Michelle
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [8] Drugging the undruggable
    Mayer, JR
    DiMarchi, RD
    CHEMISTRY & BIOLOGY, 2005, 12 (08): : 860 - 861
  • [9] Drugging the undruggable
    不详
    CHEMISTRY & INDUSTRY, 2015, 79 (12) : 57 - 57
  • [10] Drugging the undruggable
    Verdine, Gregory L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233